4/A: Kymera Therapeutics Director Adjusts Holdings

Bruce Booth, a Director at Kymera Therapeutics, has filed an amended Form 4 detailing adjustments to his beneficial ownership of common stock, primarily related to sales executed under a Rule 10b5-1 trading plan.

Summary

• This filing is an amended Form 4, correcting previous reporting errors regarding the allocation of sales between two investment entities, Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.
• Bruce Booth, a Director of Kymera Therapeutics, Inc. (KYMR), engaged in multiple transactions on June 29, 2026, involving the sale of common stock.
• These sales were conducted under a Rule 10b5-1 trading plan established on December 11, 2025.
• The reported sales involved a total of 19,419 shares from Atlas Venture Fund X and 2,698 shares from Atlas Venture Opportunity Fund I, with weighted average prices ranging from $105.78 to $111.20.
• The filing clarifies that the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the insider sales and the need for an amendment to correct reporting errors, although the sales were conducted under a pre-planned strategy.

Negatives

• The filing indicates a correction of previous reporting errors, suggesting a lack of meticulousness in the initial filing.
• Multiple sales of common stock by a director could be interpreted negatively by the market, although conducted under a pre-established plan.

Risks

• The sales were executed under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading. However, the execution of such plans by insiders can still be perceived negatively by the market.
• The need for an amendment to the original Form 4 indicates potential inaccuracies in reporting, which could raise concerns about internal controls or diligence.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions and ownership adjustments.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
• The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
• The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
• This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged.

Industry Context

StockSavvy.ai notes that insider sales, even under a Rule 10b5-1 plan, are closely watched by the market. The correction of a prior filing adds a layer of scrutiny, though the aggregate number of shares sold remains consistent.

Stakeholder Impact

• Shareholders may view the director's sales with caution, despite the Rule 10b5-1 plan, as it reduces insider ownership.
• The amendment to the filing could lead to minor confusion or questions regarding the accuracy of previous disclosures.

Key Dates

Recommendation

The filing reports on insider stock sales executed under a pre-arranged trading plan and an amendment to correct prior reporting errors. While insider sales can be a negative signal, the structured nature of the plan and the correction of clerical errors suggest it's not indicative of a fundamental change in the company's outlook. Therefore, a 'hold' recommendation is appropriate, pending further company performance updates.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Rule 10b5-1, Bruce Booth, Director, Stock Sale, Beneficial Ownership, SEC Filing, Amendment